Remove Biopharma Remove Patients Remove Specialization
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Developing best-in-class speciality enzymes.

article thumbnail

Resolving challenges with product recovery in biopharma manufacturing

Pharmaceutical Technology

Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs. This can result in reductions in costs for our customers.” Download to learn more.

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time.

article thumbnail

Embedding the Patient Point of View in Everything You Do

PM360

The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?

article thumbnail

Optimising biopharma production through process intensification

Pharmaceutical Technology

The appeal of process intensification continues to grow in the biopharma industry as a means of not only increasing the productivity, but also improving sustainability. Patients living with cancer and Alzheimer’s are two examples of groups that need access. Yet this is far from straightforward. Download to learn more.

article thumbnail

Medicinal cannabis: the route to good manufacturing practice registration

European Pharmaceutical Review

They are there to do a job and ultimately to keep patients safe. How do you see the evolution of cannabis-based medicines, particularly when it comes to the ‘specials’ or fully licensed drug routes? We are already seeing rapid growth in the UK ‘specials’ market for a variety of conditions, with some very positive patient outcomes.

Medicine 132
article thumbnail

Ashfield and Huntsworth Unite to Form Inizio

PM360

Now, the two companies will unite their full suite of advisory, medical, marketing, communications, and patient and stakeholder engagement services to create a new organization called Inizio. The unit will specialize in medical communications, medical affairs, real-world evidence, and outcomes research.